Betadex sulfobutylether sodium — a key enabler for potent neurotherapeutics
In the search for better therapies for neurodegenerative diseases like Parkinson’s, researchers are increasingly looking beyond classical drugs to the
Tag: SBECD
Sulfated β-Cyclodextrin-Mediated Antimicrobial Peptide Nanoparticles for Alkaloid Encapsulation
The β-cyclodextrin bearing an average of 13 sulfate groups (S13βCD) uniquely combines two key functions: it binds pharmaceutically relevant alkaloids
CDs for Regulating Cholesterol Homeostasis in Atherosclerosis
The progression of atherosclerosis (AS) is strongly linked to lipid crystals accumulation caused by cholesterol metabolism disorders and the worsening
Remdesivir (GS-5734) protects African green monkeys (AGM) from Nipah virus challenge
Introduction: Nipah virus is an emerging pathogen in the Paramyxoviridae family, which appers today a real threat for eventual pandemy.
Subcutaneous injection of an SBECD salt of ketamine
Conventional ketamine hydrochloride solutions are acidic and hyperosmotic, limiting their tolerability for subcutaneous (SC) delivery. BB106 is a novel ketamine
A supramolecular assembly made with sulfobutylether-β-cyclodextrin and magnetic Fe3O4 showing water remediation properties
In this paper, a magnetic hybrid system was produced by supramolecular self-assembly between low-cost precursors: the sulfobutylether-β-cyclodextrin (SBECD) and magnetic
Novel delivery systems for Resveratrol
A novel polymer, β-cyclodextrin-epichlorohydrin-cyanoguanidine polymer (CDPC) was synthesized to evaluate its potential as an efficient carrier for the encapsulation of
First EMA regulation on the residues of betadex sulfobutylether sodium in foodstuffs of animal
Regulation (European Commission) No. 470/2009 lays down Community procedures for the establishment of residue limits of pharmaceutical active substances, excipients
Cyclodextrin complexation of selected tyrosine kinase inhibitors
The comprehensive physicochemical characterization and cyclodextrin complexation of four tyrosine kinase inhibitors — erlotinib, gefitinib, vandetanib, and lapatinib — were
SQ Innovation: FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
This second-generation delivery device provides a cost-efficient alternative to in-hospital treatment. Lasix® ONYU represents the most recent FDA-approved formulation incorporating